Life Sciences Blog
17 August 2017 by
Is IRP a self sustaining dynamo or soon to be eclipsed?
4 August 2017 by Sophie Cairns
China adds another 36 medicines to NRDL
28 July 2017 by Milena Izmirlieva
What was the "Skinny Bill" and what's next?
18 July 2017 by Cameron Lockwood
At what point will payers decide that opacity in the prices being referenced renders the tool meaningless?
11 July 2017 by Mohamed Elsayed
Drug shortages and the insufficient control systems in many Middle East countries have also allowed illegal...
16 June 2017 by Praful Mehta
IHS Markit and Context Matters have for the first time combined these two diverse datasets under one platform so that companies...
8 June 2017 by Sophie Cairns
There is increasing public debate over whether Hong Kong’s cash-rich government should give more public funding to...
31 May 2017 by Milena Izmirlieva
How oil prices undermine a country's ability to pay for medicines
24 May 2017 by Margaret Labban
A deeper look at US healthcare reform
23 May 2017 by Gustav Ando
Insights from Day one at ISPOR Boston: US healthcare reform
22 May 2017 by Gustav Ando
IHS Markit's life sciences team is at ISPOR this week.
10 May 2017 by Janet Beal
Ukraine has remained the only European country where until very recently patients have largely had to pay out-of-pocket
3 May 2017 by Brendan Melck
Tensions between the pharmaceutical industry and the social security institutions in Austria are high again
13 April 2017 by Eóin Ryan
The latest analysis could facilitate future cross-border procurement structures between two or more Nordic countries
27 March 2017 by Tania Rodrigues
best IRP practice considerations from an industry standpoint
21 March 2017 by Milena Izmirlieva
A look at some of the developments in cross-country procurement and its possible negative impact for Industry
17 March 2017 by Praful Mehta
There are clear signals in the EU that the market access environment will become more stringent in the coming years
10 March 2017 by Cameron Lockwood
A look at SB-17 and what it means for drug pricing in CA
6 March 2017 by Margaret Labban
The five key principles that need to be present in new legislation that would replace the ACA
24 January 2017 by Gustav Ando
The Patient Reported Indicators Survey (PaRIS) was formally launched with the ambition of becoming the pre-eminent standard...
About the Life Sciences BlogIndustry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence. IHS Markit Blog Home »
Tweets by @IHS4LifeScience